Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Rev Esp Patol ; 56(2): 76-81, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37061245

RESUMEN

INTRODUCTION: Infantile fibrosarcoma is a rare non-rhabdomyosarcomatous soft tissue tumor (0.0005%) of which only 10% occur in the abdomen where they rarely affect the gastrointestinal tract. The median age at diagnosis is 3 months although 40% of them are present at birth. MATERIAL AND METHODS: When infantile fibrosarcoma is diagnosed in our center, a clinical-pathological description is made together with a bibliographic review. RESULTS: We present the case of a 6-day-old girl who presented with irritability and rejection of food. She was diagnosed with acute abdomen due to perforation and underwent surgery where a mass on the ascending colon was removed. Histopathology revealed a proliferation of spindle cells consisting of intertwined fascicles, infiltrating the adjacent tissues. Nuclear pleomorphism, few mitoses, foci of necrosis and hemorrhage are seen. Immunohistochemistry showed positivity for Pan-TRK and the NGS panel (Archer DX) demonstrated the TPR::NTRK1 fusion. No case with these characteristics, location or TPR::NTRK1 fusion were found in the literature. CONCLUSIONS: Infantile fibrosarcoma is a very infrequent tumor which is exceptionally rare in the intestine. It is important to look for the characteristic genetic rearrangement of these tumors both to confirm the diagnosis and differentiate them from other pediatric spindle cell tumors and determine the correct targeted treatment. Selective TRK inhibitors have shown a 75% response rate in children and adults with tumors that exhibit TRK fusion. It was possible to find fusions with the Archer DX panel that the Oncomine panel did not detect.


Asunto(s)
Fibrosarcoma , Neoplasias de los Tejidos Blandos , Recién Nacido , Adulto , Femenino , Niño , Humanos , Lactante , Receptor trkA/genética , Fibrosarcoma/genética , Fibrosarcoma/diagnóstico , Fibrosarcoma/patología , Neoplasias de los Tejidos Blandos/patología , Translocación Genética , Intestinos/patología
2.
Pathol Int ; 58(4): 249-52, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18324919

RESUMEN

Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration. Most of the examples in the literature have been reported as single cases. Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm. The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma. It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed. T-cell receptor-gamma clonal rearrangement could be also helpful in these cases. Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.


Asunto(s)
Carcinoma de Células Transicionales/diagnóstico , Linfoma Anaplásico de Células Grandes/diagnóstico , Proteínas Tirosina Quinasas/metabolismo , Neoplasias de la Vejiga Urinaria/diagnóstico , Quinasa de Linfoma Anaplásico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Transicionales/metabolismo , Cisplatino/administración & dosificación , Citarabina/administración & dosificación , Diagnóstico Diferencial , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Humanos , Antígeno Ki-1/metabolismo , Linfoma Anaplásico de Células Grandes/tratamiento farmacológico , Linfoma Anaplásico de Células Grandes/enzimología , Masculino , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Mucina-1/metabolismo , Proteínas Tirosina Quinasas Receptoras , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA